Montmorillonite/poly-(-caprolactone) composites as versatile layered material: Reservoirs for anticancer drug and controlled release property

European Journal of Pharmaceutical Sciences

Volumn 47, Issue 1, 2012, Pages 265-272

  Kevadiya, Bhavesh D ^a,b   Thumbar, Rahul P ^c   Rajput, Mahendrapalsingh M ^b   Rajkumar, Shalini ^b   Brambhatt, Harshad ^a   Joshi, Ghanshyam V ^a   Dangi, Ganga P ^a   Mody, Haresh M ^a   Gadhia, Pankaj K ^c   Bajaj, Hari C ^a  

^a CSIR CENTRAL SALT AND MARINE CHEMICALS RESEARCH INSTITUTE   (India)

^b NIRMA UNIVERSITY   (India)

^c VEER NARMAD SOUTH GUJARAT UNIVERSITY   (India)

Author keywords

Cell viability; Genotoxicity; Montmorillonite; Pharmacokinetics; Tamoxifen

Indexed keywords

KETOCONAZOLE; MONTMORILLONITE; POLYCAPROLACTONE; TAMOXIFEN CITRATE; ANTINEOPLASTIC AGENT; BENTONITE; DRUG CARRIER; POLYESTER; SODIUM; TAMOXIFEN;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL VIABILITY; COMET ASSAY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DNA DAMAGE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; FEMALE; GENOTOXICITY; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERCALATION COMPLEX; LYMPHOCYTE CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECTROSCOPY; STATIC ELECTRICITY; THERMAL ANALYSIS; X RAY DIFFRACTION; ANIMAL; BREAST TUMOR; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECT; LYMPHOCYTE; METHODOLOGY; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENTONITE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; DNA DAMAGE; DRUG CARRIERS; FEMALE; HELA CELLS; HUMANS; LYMPHOCYTES; POLYESTERS; RATS; RATS, WISTAR; SODIUM; TAMOXIFEN; X-RAY DIFFRACTION;

EID: 84864278998     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.04.009     Document Type: Article

References (34)

1. F. Bergaya, B.K.G. Theng, and G. Lagaly Handbook of Clay Science first ed. 2006 Elsevier Publication Amsterdam
2. C.M. Buchanan, N.L. Buchanan, K.J. Edgar, J.L. Little, M.O. Malcolm, and K.M. Ruble Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-b-cyclodextrinnformulations J. Pharm. Sci. 96 2007 644 660
3. D.A. Cameron, A.A. Ritchie, S. Langdon, T.J. Anderson, and W.R. Miller Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression Breast Cancer Res. Treat. 45 1997 99 107
4. M. Clemons, S. Danson, and A. Howell Tamoxifen (Nolvadex): a review Cancer Treat. Rev. 28 2002 165 180
5. D.P. De Santana, R.M.C. Braga, R. Strattmman, M.M. Albuquerque, D.C.G. Bedor, and L.B. Leal Reversed phase HPLC determination of tamoxifen in dog plasma and its pharmacokinetics after a single oral dose administration Quim. Nova. 3 2008 47 52
6. H. Devalapally, Z. Duan, M.V. Seiden, and M.M. Amiji Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles Clin. Cancer Res. 14 2008 3193 3203
7. Y. Dong, and S.S. Feng Poly(d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs Biomaterials 26 2005 6068 6076
8. S.S. Feng, L. Mei, P. Anitha, C.W. Gan, and W. Zhou Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel Biomaterials 30 2009 3297 3306
9. F. Foger, H. Hoyer, K. Kafedjiiski, M. Thaurer, and A.B. Schnurch In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein Biomaterials 27 2006 5855 5860
10. M.M. Gottesman, and I. Pastan Biochemistry of multidrug resistance mediated by the multidrug transporter Annu. Rev. Biochem. 62 1993 385-327
11. P. Greaves, R. Goonetilleke, G. Nunn, J. Topham, and T. Orton Two-year carcinogenicity study of tamoxifen in alderley park wistar-derived rats Cancer Res. 53 1993 3919 3924
12. X.L. Han, and J.G. Liehr Induction of covalent DNA adducts in rodents by tamoxifen Cancer Res. 52 1992 1360 1363
13. D.A. Hungerford Leukocytes cultured from small inocula of whole blood and the preparation of chromosomes by treatment with hypotonic KCI Stain Technol. 40 1965 333 338
14. F.X. Hu, K.G. Neoh, and E.T. Kang Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles Biomaterials 27 2006 5725 5733
15. H.G. Jagadeesh, and K.V. Devi Tamoxifen loaded poly (-caprolactone) based injectable microspheres for breast cancer Int. J. Pharm. Pharm. Sci. 2 2010 189 195
16. A.K. Jain, N.K. Swarnakar, C. Godugu, R.P. Singh, and S. Jain The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen Biomaterials 32 2011 503 515
17. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and T. Murray Cancer statistics CA Cancer J. Clin. 58 2008 71 96
18. V.C. Jordan Tamoxifen: a most unlikely pioneering medicine Nat. Rev. Drug Discov. 2 2003 205 213
19. G.V. Joshi, B.D. Kevadiya, H.A. Patel, H.C. Bajaj, and R.V. Jasra Montmorillonite as a drug delivery system: intercalation and in vitro release of timolol maleate Int. J. Pharm. 374 2009 53 57
20. B.D. Kevadiya, G.V. Joshi, and H.C. Bajaj Layered bionanocomposites as carrier for procainamide Int. J. Pharm. 388 2010 280 286
21. C.K. Lim, Z.X. Yuan, J.H. Lamb, I.N. White, F. De Matteis, and L.L. Smith A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes Carcinogenesis 15 1994 589 593
22. F.H. Lin, Y.H. Lee, C.H. Jian, J.M. Wong, M.J. Shieh, and C.Y. Wang A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier Biomaterials 23 2002 1981 1987
23. E.A. Martin, K. Brown, M. Gaskell, F. Al-Azzawi, R.C. Garner, and D.J. Boocock Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry Cancer Res. 63 2003 8461 8465
24. C.J. Matheny, M.W. Lamb, K.L. Brouwer, and G.M. Pollack Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation Pharmacotherapy 21 2001 778 796
25. G. Pagano, A. de Biase, I.B. Deeva, P. Degan, Y.K. Doronin, and M. Iaccarino The role of oxidative stress in developmental and reproductive toxicity of tamoxifen Life Sci. 68 2001 1735 1749
26. D.H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis 22 2001 839 849
27. M.C. Poirier, and L.J. Schild The genotoxicity of tamoxifen: extent and consequences, Kona Hawaii, January 23, 2003 Mutagenesis 18 2003 395 399
28. G.K. Poon, Y.C. Chui, R. McCague, P.E. Llnning, R. Feng, M.G. Rowlands, and M. Jarman Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients Drug Metab. Dispos. 21 1993 1119 1124
29. B. Sahana, K. Santra, S. Basu, and B. Mukherjee Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in vitro evaluation Int. J. Nanomed. 5 2010 621 630
30. Y. Shang, and M. Brown Molecular determinants for the tissues specificity of SERMs Science 295 2002 2465 2468
31. N.P. Singh, M.T. McCoy, R.R. Tice, and E.L. Schneider A simple technique for quantitation of low levels of damage in individual cells Exp. Cell Res. 175 1988 184 191
32. J.M.M. Terwogt, J.H. Beijnen, W.W.T. Huinink, H. Rosing, and J.H.M. Schellens Coadministration of cyclosporin enables oral therapy with paclitaxel Lancet 352 9124 1998 285
33. M.D. Troutman, and D.R. Thakker Rhodamine 123 requires carriermediated influx for its activity as a P-glycoprotein substrate in CaCo-2 cells Pharm. Res. 20 2003 1192 1199
34. K. Wozniak, A. Kolacinska, M.B. Morawiec, A.M. Bajda, Z. Morawiec, and M. Zadrozny The DNA-damaging potential of tamoxifen in breast cancer and normal cells Arch. Toxicol. 81 2007 519 527